Cyclacel removes ownership limitation on Series F Convertible Preferred Stock

Bio Green Med Solution, Inc.

Filed Amended Certificate of Designation removing Series F Ownership Limitation that capped conversion/voting at 4.99% of common stock.
Effective July 28, 2025, after board and majority stockholder approval per Schedule 14C filed July 7, 2025.
No other changes to Series F Convertible Preferred terms; removal allows unrestricted conversion and voting.
Potential for increased dilution if holders convert shares without prior ownership cap.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bio Green Med Solution, Inc.: Filing of Amended and Restated Certificate of Designations for Series F Convertible Preferred Stock removing the Series F Ownership Limitation (effective 2025-07-28).

Change: charter amendment
Effective: 2025-07-28

Exact text from the filing

On July 28, 2025, after obtaining the approval of the Board of Directors and majority stockholder of Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the “Company”) as disclosed in the Company’s Definitive Information Statement on Schedule 14C filed with the Securities and Exchange Commission on July 7, 2025 (the “Schedule 14C”), the Company filed an Amended and Restated Certificate of Designations, Preferences, Rights and Limitations of Series F Convertible Preferred Stock (the “Restated Certificate of Designation”) with the Secretary of State of the State of Delaware.

View on SEC.gov

275 governance changes filed in the last 30 days. Browse all governance changes →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-021159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.